• / Free eNewsletters & Magazine
  • / My Account
Home>Finance>Technology>Biotechnology

Biotechnology

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. TNI BioTech , Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend

    TNI BioTech , Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend

  2. RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum

    RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum

  3. Roche purchases shares in tender offer for InterMune, Inc.

    Roche purchases shares in tender offer for InterMune, Inc.

  4. Three Marshall, Gerstein & Borun Biotechnology Partners Selected Among Top 250 Women in IP

    Three Marshall, Gerstein & Borun Biotechnology Partners Selected Among Top 250 Women in IP

  5. Ignyta Announces Interim Data from RXDX-101 Phase I Clinical Trial at 2014 ESMO Congress

    Ignyta Announces Interim Data from RXDX-101 Phase I Clinical Trial at 2014 ESMO Congress

  6. Sevion Therapeutics Reports Fiscal Year 2014 Financial Results

    Sevion Therapeutics Reports Fiscal Year 2014 Financial Results

  7. U.S. Patent and Trademark Office Issues Can-Fite Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery

    U.S. Patent and Trademark Office Issues Can-Fite Patent for CF102 in the Treatment of Liver Regeneration and Function Following Surgery

  8. Georgia Bio and UCB to Host Parkinson’s Gala Benefitting the National Parkinson Foundation, Wilkins Parkinson's Foundation

    Georgia Bio and UCB to Host Parkinson’s Gala Benefitting the National Parkinson Foundation, Wilkins Parkinson's Foundation

  9. Genentech’s Perjeta Regimen Extended the Lives of People With an Aggressive Type of Metastatic Breast Cancer by 15.7 Months Compared to Herceptin and Chemotherapy

    Genentech’s Perjeta Regimen Extended the Lives of People With an Aggressive Type of Metastatic Breast Cancer by 15.7 Months Compared to Herceptin and Chemotherapy

  10. Roche Gets Nearly 80% of InterMune Stock in Tender Offer

    Roche Gets Nearly 80% of InterMune Stock in Tender Offer

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.